Is tumour heterogeneity an issue when assessing PD-L1 status?
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 01:00
Prof. John Gosney explains shares how to overcome the challenges of tumour heterogeneity when testing for PD-L1 in NSCLC. This video was filmed in January 2017.
Join PinPoint to keep updated with the latest educational materials in PD-L1 testing
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
GB-PDO-01090 | Date of Preparation: September 2020